Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

ClinicalTrials.gov ID: NCT06340360

Public ClinicalTrials.gov record NCT06340360. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Study identification

NCT ID
NCT06340360
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Nektar Therapeutics
Industry
Enrollment
94 participants

Conditions and interventions

Interventions

  • Rezpegaldesleukin Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 1, 2024
Primary completion
Nov 25, 2025
Completion
Jul 31, 2026
Last update posted
Jul 9, 2026

2024 – 2026

United States locations

U.S. sites
10
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Nektar Investigative Site Northridge California 91324
Nektar Investigative Site Atlanta Georgia 30331
Nektar Investigative Site Gurnee Illinois 60031
Nektar Investigative Site Indianapolis Indiana 46202
Nektar Investigative Site Clinton Township Michigan 48038
Nektar Investigative Site Portsmouth New Hampshire 03801
Nektar Investigative Site New York New York 10075
Nektar Investigative Site Camp Hill Pennsylvania 17011
Nektar Investigative Site Frisco Texas 75034
Nektar Investigative Site Pflugerville Texas 78660

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06340360, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 9, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06340360 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →